Publications by authors named "Rebekka L Hansen"
Article Synopsis
- The study aimed to understand the concerns and needs of adults living with spondyloarthropathies (SpA) through participants’ perspectives on disease and treatment-related issues.
- Using group concept mapping (GCM), participants produced and organized numerous statements into concepts, allowing them to rate the importance of each concern.
- The results highlighted significant issues across different diseases, such as the need for understanding from healthcare professionals in axial spondyloarthritis and the impact of social problems in psoriasis.
Objectives: To assess the effectiveness and tolerability of first- and second-line interleukin (IL)-17A inhibitor treatment in PsA patients from 2014 to 2021 using data from the Danish Rheumatology Registry (DANBIO) by investigating adherence to therapy.
Method: PsA patients recorded in the DANBIO who received a first- or second-line IL-17A inhibitor treatment were included in this study. All patients included had previously received one or more TNF inhibitor treatment.
Objective: To investigate the influence of comorbidities on treatment response, disease activity and persistence with first-line IL-17 inhibitor (IL-17i) treatment in patients with PsA.
Methods: Patients were divided into three groups depending on the presence and/or severity of comorbidities using the Charlson Comorbidity Index (CCI). Groups were CCI 0: no comorbidities, CCI 1: one comorbidity and CCI ≥2: two or more comorbidities or one or more severe comorbidities.
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.
Arthritis Care Res (Hoboken)
May 2022
Article Synopsis
- The study aimed to compare the effectiveness of secukinumab and tumor necrosis factor inhibitors (TNFi), particularly adalimumab, in treating patients with spondyloarthritis (SpA).
- Data were collected from Nordic rheumatology registries on patients starting treatment between 2015 and 2018, focusing on comorbidities and treatment outcomes like retention rates and response to therapy after 6 months.
- Results showed that secukinumab had similar 1-year retention rates as adalimumab for first and second-line treatments but significantly lower retention in third-line treatments, along with poorer 6-month response rates across all treatment lines.
Objective: The objective of this population-based cohort study was to investigate the association between fatigue with disease activity and drug survival in patients with psoriatic arthritis (PsA) receiving their first tumor necrosis factor inhibitor (TNFi).
Methods: Data on patient characteristics, disease activity, and drug survival were obtained from the DANBIO database on all patients with PsA from 2006 through 2015. Information on comorbidities was obtained through linkage with the Danish National Patient Registry.